A surge in Inventiva shares, up about 50% in the first few weeks of 2026, highlights investors' appetite for betting on the loss-making French biotech, which is on the verge of entering the fast-grow... ...

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even though momentum is a popular stock characte ...

Company Overview - Inventiva has undergone a significant transformation in the last 18 months, indicating a strategic shift or development within the organization [4] - The company is currently conducting a fully enrolled Phase III trial for its lead asset, lanifibranor, which is positioned as a potential best-in-class oral therapy for MASH [4] Clinical Development - The Phase III trial design is based on a successful Phase IIb trial involving over 200 patients, which was published in the New England Journal of Medicine with positive results [4] - The readout for the Phase III trial is anticipated in the second half of this year, suggesting a critical upcoming milestone for the company [4] Financial Position - The company has received a substantial amount of funding, which may support its ongoing clinical trials and operational activities [5]

Summary of Inventiva's Presentation at JPMorgan Healthcare Conference Company Overview - **Company**: Inventiva - **CEO**: Andrew Openshin - **Lead Asset**: Lanifibranor, an oral therapy for MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease) - **Recent Transformation**: The company has undergone significant changes in the last 18 months, including a fully enrolled phase three trial and substantial funding [2][3] Financial Highlights - **Funding**: - $411 million raised in October 2024 - Additional $172 million raised in October [3] - **Cash Balance**: Expected to last until Q3 2027, assuming positive data from trials [21] Clinical Development - **Phase 3 Trial**: - Fully recruited with over 1,000 patients enrolled - Anticipated readout in the second half of the year - Focus on F2 and F3 patient populations, excluding F1 patients [3][17] - **Phase 2b Results**: - 18% effect size on fibrosis and 24% on MASH resolution - Significant improvements in cardiometabolic markers [11][12] Market Opportunity - **MASH Market Size**: Expected to grow to $15 billion by 2035 - **Current Diagnosis Rate**: Approximately 2 million diagnosed MASH patients in the U.S., representing a 25% increase since 2024 [5][6] - **Target Patient Population**: F2 and F3 patients, approximately 375,000 in the U.S. [6] Competitive Landscape - **Treatment Evolution**: - GLP-1 therapies are expected to be the backbone for F1, F2, and F3 patients - Lanifibranor positioned as a complementary oral therapy [7][8] - **Safety Profile**: - Low rates of peripheral edema (2%) and milder weight gain compared to previous PPAR agonists [15][16] Future Plans - **Outcomes Trial**: Planned for patients with compensated cirrhosis MASH to confirm clinical benefits [18] - **Market Launch**: Anticipated for 2028, with strategic preparations ongoing for commercialization in 2026 [20][21] Management and Strategy - **Management Team**: Strengthened with experienced professionals from Intercept and Ipsen [4] - **Strategic Preparation**: Focus on market research and building medical affairs presence in 2026 [24] Additional Insights - **Patient Impact**: Emphasis on the potential to reverse stages of fibrosis and improve patient outcomes [22] - **Company Positioning**: Plans to remain France-based while expanding U.S. commercial infrastructure [23] This summary encapsulates the key points from Inventiva's presentation, highlighting the company's strategic direction, clinical developments, market opportunities, and future plans.

Lanifibranor's Potential - Lanifibranor is presented as a potential best-in-disease oral therapy for MASH (Metabolic dysfunction-Associated SteatoHepatitis), targeting progressive fibrosis in F2/F3 MASH patients[1,5] - The company anticipates regulatory filings in 2027 and a potential commercial launch in 2028, pending approval[8] - Phase 2b trial data showed a 24% effect size on the dual endpoint of fibrosis improvement and MASH resolution in just 24 weeks[70] - The Phase 3 NATiV3 clinical trial is fully recruited with 1,009 patients in the main cohort and 410 in the exploratory cohort[56] - Topline data from the Phase 3 trial is expected in the second half of 2026[8,64] MASH Market and Medical Understanding - The MASH market is expected to exceed $15 billion by 2035[15] - Approximately 19 million were diagnosed with MASH in the U S in 2025, representing ~10% of the patients with MASH[13] - Approximately 910,000 patients have clinically actionable F2/F3 disease, with about 374,000 (~40%) under treated care[14] Financial Position - The company raised $172 million from investors in November 2025[8] - The company's cash runway extends until the middle of Q3 2027, assuming full exercise of the 3rd tranche[8,67]

Shares of Inventiva S.A. Sponsored ADR (IVA) have gained 13.8% over the past four weeks to close the last trading session at $5.1, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $15.33 indicates a potential upside of 200.6%.The mean estimate comprises nine short-term price targets with a standard deviation of $7.25. While the lowest estimate of $3.00 indicates a 41.2% decline f ...

Core Insights - Inventiva, a clinical-stage biopharmaceutical company, focuses on developing oral therapies for metabolic dysfunction-associated steatohepatitis (MASH) [1][2] Group 1: Corporate Overview - CEO Andrew Obenshain will present a corporate overview and engage in investor meetings at the 44th Annual J.P. Morgan Healthcare Conference from January 12-15, 2026 [1] - The presentation is scheduled for January 15, 2026, from 9:00 am to 9:40 am (PST) at The Westin St. Francis Hotel, San Francisco, California [2] Group 2: Product Development - Inventiva is evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for treating adult patients with MASH [2]

Group 1 - U.S. stock futures are higher, with Dow futures gaining around 50 points [1] - Tilray Brands Inc announced a one-for-10 reverse stock split, effective December 1 [1] - Tilray shares fell sharply by 15% to $0.88 in pre-market trading [2] Group 2 - Inventiva ADR fell 7.4% to $4.26 in pre-market trading after a previous gain [4] - Anglogold Ashanti PLC dipped 5.5% to $83.97 in pre-market trading after a gain of over 5% [4] - Lexicon Pharmaceuticals Inc fell 5% to $1.36 in pre-market trading [4] - SuperX AI Technology Ltd fell 3.9% to $26.00 in pre-market trading after a significant previous jump of 23% [4] - Palisade Bio Inc declined 3.6% to $2.15 in pre-market trading [4] - Gold Fields Ltd fell 3.4% to $41.76 in pre-market trading after a gain of 6% [4] - Abacus Global Management Inc fell 3.2% to $6.33 in pre-market trading after reporting better-than-expected third-quarter results and announcing a $10 million buyback [4]

Core Points - Inventiva, a clinical-stage biopharmaceutical company, focuses on developing oral therapies for metabolic dysfunction-associated steatohepatitis (MASH) and announced the results of its Combined Shareholders' Meeting held on November 27, 2025 [1][10]. Voting Results - All resolutions submitted to the shareholders were adopted, except for resolution 5, which was negatively recommended by the Board of Directors. This resolution aimed to empower the Board to decide on share capital increases for a company savings plan [3][4]. - The Combined Shareholders' Meeting had a total of 441 shareholders represented, with a total of 119,608,674 votes cast, achieving a quorum of 56.432% [5]. - In the ordinary resolutions, the votes for resolutions ranged from 89.7% to 99.9% in favor, with the highest support for resolution 6 [6][7]. - In the extraordinary resolutions, resolution 4 was adopted with 89.9% in favor, while resolution 5 was rejected with only 41.6% support [8][9]. Company Overview - Inventiva is publicly listed on Euronext Paris and Nasdaq, focusing on the research and development of oral small molecule therapies for MASH and other diseases with significant unmet medical needs. The company is currently evaluating lanifibranor in a pivotal Phase 3 clinical trial [10][11].

Core Viewpoint - The press release provides information regarding the stabilization activities related to the recent public offering of Inventiva in the United States, which involved the issuance of 38,961,038 American Depositary Shares (ADSs) and an additional 5,844,155 ADSs purchased by underwriters [1][2]. Group 1: Offering Details - The public offering consisted of 38,961,038 ADSs, with an additional 5,844,155 ADSs purchased by underwriters [1][2]. - The offer price for each ADS was set at $3.85 [2]. - The stabilization activities were conducted by Piper Sandler, which acted as the stabilization agent [2]. Group 2: Stabilization Activities - The stabilization period commenced on November 13, 2025, and concluded on November 17, 2025 [2]. - On November 13, 2025, Piper Sandler executed a buy transaction for 20,700 shares at an average price of $3.6933, with a total transaction amount of $76,451.31 [2].